Speakers & Presenters

Hong Kong,

Olivia Albrecht

STRATEGIC ADVISOR, PERSEFONI

Harnessing the Power of Biotechnology on ESG Issues

David Apelian

CEO, BLUESPHERE BIO, INC.

BlueSphere Bio

Pittsburgh, Pennsylvania, United States

Judy Ashworth, MD

CHIEF MEDICAL OFFICER, PINNEY ASSOCIATES

Ceruvia Lifesciences, Inc.

Greenwich, Connecticut, United States

Mara Aspinall

FOUNDER & MANAGING DIRECTOR, BLUESTONE VENTURE PARTNERS

Defining Correlates of Protection for COVID-19: The Technology is Here, The Time is Now

Tucson, Arizona, United States

Diana Attia

EXECUTIVE DIRECTOR, MSD

Oss,

Trond Erik Aune, PhD

CEO, VECTRON BIOSOLUTIONS AS

Vectron Biosolutions AS

Trondheim, Norway

Suzanne Babcock

EXECUTIVE CHAIRMAN & CO-FOUNDER, CIVATECH ONCOLOGY

CivaTech Oncology

Durham, North Carolina, United States

Martin Babler

PRESIDENT AND CEO, CHAIRMAN OF THE BOARD, ALUMIS, INC.

How to Survive a Stormy Biotech Season: Thriving in a Challenging Market

South San Francisco, California, United States

Mark Bach, PhD

CHIEF MEDICAL OFFICER, SHOUTI

Ending The Cycle of Chronic Disease: Leveraging New Therapeutic Approaches with Disease-Modifying Potential

Don Bailey, DrPH

DISTINGUISHED FELLOW, RTI INTERNATIONAL

Modernizing Newborn Screening: High Patient Impact, Big Challenges

Bryan Baines

DIRECTOR, DUKE UNIVERSITY

Impactful Models and Resources for De-risking and Translating University-Held Innovations

Wake Forest, North Carolina, United States

Machelle Baker Sanders

SECRETARY OF COMMERCE, NC DEPARTMENT OF COMMERCE

Building a Strong Biomanufacturing Workforce in the United States: A Conversation with State Economic Development Experts

Michael Banyas

HEALTH SPECIALIST, NIH NATIONAL INSTITUTE ON MINORITY HEALTH DISPARITIES

Fostering Diversity and Bio-Equity Through Novel Financing and Training Initiatives in the Aging Innovation Ecosystem

Bethesda, Maryland,

Marta Barrachina, MBA;PhD

CEO, ADMIT THERAPEUTICS S.L.

ADmit Therapeutics SL

ESPLUGUES DE LLOBREGAT, Spain

Alison Bateman-House, PhD, MA, MPH

ASSISTANT PROFESSOR, NYU LANGONE HEALTH

Individualized Therapeutics: Walking the Line Between Research and Treatment

Hernan Bazan

CEO AND CO-FOUNDER OF SOUTH RAMPART PHARMA; PROFESSOR OF SURGERY, INNOVATION, OCHSNER HEALTH

South Rampart Pharma, LLC

New Orleans, Louisiana, United States

Loren Becker, MPP

ASSOCIATE PRINCIPAL, VACCINE POLICY AND MARKET ACCESS, AVALERE HEALTH

COVID-19 360°: Embedding Global Best Practices in Routine Regulatory Action and Preparing for the Next Pandemic

Washington, District of Columbia, United States

Jacob Becraft, PhD

CO-FOUNDER & CEO, STRAND THERAPEUTICS

Faster and Stronger: How RNA Will Advance Precision Medicine and Accessibility

Boston, Massachusetts,

Susan Begelman, MD

VICE PRESIDENT OF THE US RESPIRATORY AND INFLUENZA FRANCHISES , GENENTECH

The Future of Flu Protection: Novel Influenza Technologies

Ann Beliën, PhD

CEO, REJUVENATE BIO

Heusden-Zolder, Belgium

Tim Belski

, BARDA

Getting Back to Good: USG Investments Manufacturing and Supply Chain

Rich Bendis

FOUNDER, PRESIDENT AND CEO, BIO HEALTH INNOVATION

Building Bio Facilities and Bio Ecosystems: Federal, State and Private Resources

Rockville, Maryland,

Sharon Benzeno, PhD, MBA

CHIEF COMMERCIAL OFFICER, IMMUNE MEDICINE, ADAPTIVE BIOTECHNOLOGIES

Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking

Defining Correlates of Protection for COVID-19: The Technology is Here, The Time is Now

New York, New York,

Neil Berkley

CHIEF BUSINESS OFFICER, ABCELLERA BIOLOGICS

Maximizing the Potential of Platforms Through Creative and Effective Deal-Making Strategies

San Diego, California, United States

Sulagna Bhattacharya

CO-FOUNDER & CEO, NANOSCOPE THERAPEUTICS, INC.

Nanoscope Therapeutics

Bedford, Texas, United States

Katherine Bliss

, CSIS

Innovations in COVID-19 Therapeutics: Technologies for the Next Pandemic

Jeff Bockman, PhD

EVP, ONCOLOGY PRACTICE HEAD, CELLO HEALTH BIOCONSULTING

Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking

Florham Park, New Jersey, United States

Travis Bond

CEO & FOUNDER, ALTOIDA

Altoida

Washington, Washington,

Brigid Bondoc

OF COUNSEL, MORRISON & FOERSTER LLP

FDA's RWE Grantees: One Year On

Washington,

Natasha Bonhomme

CHIEF STRATEGY OFFICER, GENETIC ALLIANCE

Modernizing Newborn Screening: High Patient Impact, Big Challenges

Christopher Boone

VP, GLOBAL HEAD OF HEALTH ECONOMICS & OUTCOMES RESEARCH, ABBVIE

Enabling and Supporting Efficacy-Linked Pricing Contracts

North Chicago, Illinois,

Fatima Bosch, PhD

FULL PROFESSOR OF BIOCHEMISTRY AND MOLECULAR BIOLOGY AND DIRECTOR OF THE CENTER OF ANIMAL BIOTECHNOLOGY AND GENE THERAPY AT THE UNIVERSITAT AUTòNOMA BARCELONA, UNIVERSITAT AUTòNOMA BARCELONA

Gene Therapy Pioneers Discuss What's Next for Gene Therapy

François BOUTIGNON, PhD

PRESIDENT & CEO, APTYS PHARMA

APTYS PHARMA

SAINT- BEAUZIRE, Auvergne-Rhone-Alpes, France

Christopher Boyer

CHIEF BUSINESS OFFICER, TESSARA THERAPEUTICS PTY LTD

Tessara Therapeutics Pty Ltd

Southbank, Australia

Steven Braithwaite

CHIEF EXECUTIVE OFFICER, ALKAHEST, INC.

San Carlos, California, United States

Isaac Bright, MD

CEO, RUBRYC THERAPEUTICS, INC.

RubrYc Therapeutics, Inc.

San Carlos, California, United States

Max Bronstein

ASSISTANT DIRECTOR FOR HEALTH INNOVATION, OFFICE OF SCIENCE AND TECHNOLOGY POLICY

Modernizing Newborn Screening: High Patient Impact, Big Challenges

Caitlin Brown, PhD

HEAD OF BUSINESS DEVELOPMENT, PEPPER BIO

Pepper Bio

Dedham, Massachusetts, United States

Leigh Bruhn

EVP, SYNEOS HEALTH

Can Patient Perspectives Break Through Value Assessments That Rely on the QALY?

New York, New York, United States

Darren Buchwald

SVP, VACCINES AND PHARMACEUTICAL PRODUCTS, AMYRIS, INC.

Amyris

Emeryville, California, United States

Matt Buckley, PhD

COFOUNDER, RETRO BIOSCIENCES

Development of Points to Consider: Comparability Considerations for Advanced Therapy Medicinal Products Subject to Changes in their Manufacturing Process

Redwood City, California, United States

Karim Budhwani, PhD

CEO, CERFLUX, INC.

Cancer Trials Don’t Have To Fail 90% of the Time. Seriously.

Birmingham, Alabama, United States

Jennifer Buell

CEO, MINK THERAPEUTICS

Next Gen Oncology Therapeutics: Changing the Cancer Landscape

Lexington, Massachusetts,

Alex Burgin

SR DIRECTOR, THE BROAD INSTITUTE

Feeding the Pipeline

Cambridge, Massachusetts, United States

Christopher Burns, PhD

PRESIDENT AND CEO, VENATORX PHARMACEUTICALS, INC.

Venatorx Pharmaceuticals

Malvern, Pennsylvania,

Clara Burtenshaw

PARTNER AND INVESTOR , NEO KUMA VENTURES

Psychedelics: What Will It Take To Get Them to Market?

London,

George Cagna

CEO, KIFFIK BIOMEDICAL

Kiffik Biomedical Inc.

Providence, Rhode Island, United States

Stacie Calad-Thomson

CHIEF STRATEGY OFFICER AND HEAD OF DRUG DISCOVERY, BIOSYMETRICS

BioSymetrics

Huntington, New York, United States

Riccardo Canevari

CEO, RADIOPHARM THERANOSTICS

Radiopharm Theranostics

Carlton, Western Australia, Australia

Ping Cao

VP BUSINESS DEVELOPMENT, HENLIUS BIOTECH

Shanghai Henlius Biotech, Inc.

Milpitas, California, United States

James Cappuccio

MANAGING DIRECTOR, H.C. WAINWRIGHT & COMPANY

Utilizing an Existing SPAC To Take Your Private Biotech Company Public

New York, New York,

Steve Carney

EDITOR, DRUG DISCOVERY TODAY, ELSEVIER

Psychedelics: What Will It Take To Get Them to Market?

London,

Lauren Cautilli

MANAGER, SBD EXTERNAL EVENT OPERATIONS, BRISTOL MYERS SQUIBB

Bristol Myers Squibb

Langhorne, Pennsylvania, United States

Hemmie Chang

PARTNER & CO-CHAIR, LIFE SCIENCES GROUP; CHAIR, LICENSING & STRATEGIC ALLIANCES PRACTICE, FOLEY HOAG LLP

Navigating Asia-Pacific Innovation Deal Opportunities

Boston, Massachusetts, United States

Andrew Chang

VICE PRESIDENT, QUALITY AND REGULATORY COMPLIANCE, QI&I, NOV, NOVO NORDISK

Washington DC, District of Columbia, United States

John Chant, PhD

CEO, FILTRICINE, INC

Filtricine, Inc.

Santa Clara, California, United States

Rick Chapman

CHIEF SCIENCE OFFICER, INNOVATION AND VALUE INITIATIVE

Can Patient Perspectives Break Through Value Assessments That Rely on the QALY?

Boston, Massachusetts,

Nagendra Chemuturi

SCIENTIFIC DIRECTOR RESEARCH, TAKEDA ONCOLOGY

Safety Aspects of AAV- and Lentivirus-based Cell and Gene Therapy

Cambridge, Massachusetts,

Po Chen

CEO, CANCERFREE BIOTECH LTD.

CancerFree Biotech Ltd.

Taipei City, Taiwan

Michael Choi

CHIEF BUSINESS OFFICER, CSTONE PHARMACEUTICALS

Navigating Asia-Pacific Innovation Deal Opportunities

Shanghai, China

Judy Chou, PhD

CEO AND PRESIDENT, ALTRUBIO, INC.

AltruBio Inc.

San Francisco, California, United States

Jennifer Chow

CEO AND MANAGING DIRECTOR , CHIMERIC THERAPEUTICS

Chimeric Therapeutics

Oakville, Ontario, Canada

Robert Chu

CEO, EMBLEEMA

Embleema

Metuchen, New Jersey, United States

Eddie Chung

CEO, COASTAR THERAPEUTICS, INC.

Coastar Therapeutics Inc.

San Diego, California, United States

Jordan Clark, MPhil

CHIEF COMMERCIAL OFFICER, DIACEUTICS

Challenges in Implementing Personalized Medicine in Clinical Practice

London,

Matthew Clark, PhD, PMP

BOARD MEMBER AND ADVISOR, CERFLUX, INC.

Cancer Trials Don’t Have To Fail 90% of the Time. Seriously.

Gaithersburg, Maryland, United States

Jacqueline Corrigan Curay

PRINCIPAL DEPUTY CENTER DIRECTOR , FDA

Narrowing the Health Equity Gap Through Clinical Research

David Crean, PhD, MBA, MS

MANAGING PARTNER, CARDIFF ADVISORY LLC

Persuasive Pitching – Do You Have the Talent to Engage Investors?

Cardiff By The Sea, California, United States

Imran Cronk

CEO, RIDE HEALTH

Kevin Curran, PhD

SCIENTIFIC ADVISOR AND INSTRUCTOR, BIOTECH PRIMER

Introduction to Gene Therapy

Pam Cusick

SENIOR VICE PRESIDENT, RARE PATIENT VOICE

Participant Sensitivity: Amplifying the Voice of the Patient in Clinical Trials

Towson, Maryland, United States

Amy Cusick

SENIOR PROPERTY & CASUALTY RISK, RISK ENGINEERING SERVICES, CHUBB

Limiting what could be Limitless: Minimizing risk through effective business contingency planning

Whitehouse Station, New Jersey, United States

Kenneth Custer, PhD

VICE PRESIDENT, BUSINESS DEVELOPMENT AND LILLY NEW VENTURES, ELI LILLY AND COMPANY

Maximizing the Potential of Platforms Through Creative and Effective Deal-Making Strategies

Indianapolis, Indiana, United States

Jie Liu D'Elia, PhD, MBA

SRVP, ONCOLOGY, HEMATOLOGY, CELL THERAPY MEDICINE, BRISTOL MYERS SQUIBB

Wisdom and Wagers: Perspectives from Big Pharma Dealmakers

Trenton, New Jersey, United States

Igor DaCruz

MANAGING DIRECTOR, RUNWAY GROWTH CAPITAL

Options for Raising Capital in a Down Market

San Diego, California, United States

William Dalton, PhD, MD

FOUNDER, M2GEN

Cancer Trials Don’t Have To Fail 90% of the Time. Seriously.

Tampa, Florida,

Moya Daniels, MS

SVP, REGULATORY AND QUALITY, ARUVANT SCIENCES, INC.

Aruvant Sciences

Millburn, New Jersey, United States

Hiroki Danno

CEO, KNOWLEDGE PALETTE

Knowledge Palette, Inc.

Kanagawa, Japan

Brian Darmody

CEO, ASSOCIATION OF UNIVERSITY RESEARCH PARKS

Building Bio Facilities and Bio Ecosystems: Federal, State and Private Resources

College Park, Maryland,

Nataraj Dasgupta

VICE PRESIDENT, ADVANCED ANALYTICS, RXDATASCIENCE INC., A DIVISION OF SYNEOS HEALTH

How Digital Health Technical Innovation is Driving Decentralized Clinical Trial Success

Apex, North Carolina, United States

Allen Davidoff, PhD

CEO AND PRESIDENT, XORTX THERAPEUTICS

XORTX Therapeutics Inc.

Calgary, Alberta, Canada

Michael Davies

CEO & FOUNDER, CAROCELL BIO

Carocell Bio

Durham, North Carolina, United States

Melika Davis, MS

SENIOR VICE PRESIDENT, BEIGENE

Narrowing the Health Equity Gap Through Clinical Research

Khrystal K Davis, JD

FOUNDING PRESIDENT, TEXAS RARE ALLIANCE

Fireside Chat: The Accelerated Approval Pathway and the Importance to Patients

Austin, Texas, United States

Marianne De Backer, MSc, PhD, MBA

CHIEF BUSINESS OFFICER, EVP, HEAD OF PHARMACEUTICALS STRATEGY, BUSINESS DEVELOPMENT & LICENSING/OPEN INNOVATION AND MEMBER OF EXECUTIVE COMMITTEE, BAYER

Cultivating innovation post acquisition: Bayer and Vividion’s arm’s length model

Agustin de la Calle, PhD

CBO, EUTILOGICS

Eutilogics, Inc.

San Diego, California, United States

Chathuranga De Silva

DIRECTOR OF BUSINESS DEVELOPMENT, BIOCENTRIQ

BioCentriq

Newark, New Jersey,

Andrea de Souza

VP - GLOBAL HEAD, DATA SCIENCES AND ENGINEERING , ELI LILLY AND COMPANY

Why the FDA Will Bet More on in Silico Simulations To Trigger Better Success Rates for NDAs

Allison DeAngelis

SENIOR HEALTHCARE REPORTER, STAT

CNS Drug Development: Do Biomarkers Hold the Future for Patients?

Faster and Stronger: How RNA Will Advance Precision Medicine and Accessibility

Boston, Massachusetts,

Kristen DeBord

ACTING DEPUTY DIRECTOR, OFFICE OF STRATEGY, POLICY, PLANNING, AND REQUIREMENTS, HHS

Getting Back to Good: USG Investments Manufacturing and Supply Chain

The Future of Flu Protection: Novel Influenza Technologies

Bryan Dechairo, PhD

PRESIDENT & CEO, SHERLOCK BIOSCIENCES

Sherlock Biosciences

Watertown, Massachusetts, United States

R. Angelo Declaro

, FDA

Equity by Design: Utility of a Metrics Framework and Metrics To Evaluate Progress on Diversity, Equity, and Inclusion in Clinical Research

District Of Columbia,

Willyanne DeCormier Plosky, DrPH

PROGRAM MANAGER, MULTI-REGIONAL CLINICAL TRIALS CENTER OF BRIGHAM AND WOMEN’S HOSPITAL AND HARVARD , MRCT CENTER OF HARVARD AND BWH

Narrowing the Health Equity Gap Through Clinical Research

Cambridge, Massachusetts, United States

Tom DeFay, PhD

DEPUTY HEAD OF DIAGNOSTICS STRATEGY , ALEXION PHARMACEUTICALS

Advancing Policies to Shorten the Rare Disease Patient’s Diagnostic Journey

Kathryn DeFea, PhD

CEO, PARMEDICS

PARMedics

Temecula, California, United States

Jennifer Dent

PRESIDENT, BIO VENTURES FOR GLOBAL HEALTH

Achieving Global Health Equity with BioPharma and Medtech

Seattle, Washington,

Lopa Desai, BS, BA

FORMER SVP, GLOBAL COMMERCIAL OPERATIONS & MARKET ACCESS, ARENA PHARMACEUTICALS, INC.

Out-License, Co-Promote, or Solo-First launch? Insights From an Expert Panel and a Decade of U.S. and EU First-Launch and Partnering Data

San Diego, California,

Scott DeWire

HEAD OF US BUS. DEV. & LICENSING, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

Boehringer Ingelheim Pharmaceuticals, Inc.

Ridgefield, Connecticut, United States

Nick Diamond

DIRECTOR, CROWELL & MORING INTERNATIONAL

Vaccine Innovation and the Future of Life-Course Immunization

Washington, District of Columbia, United States

Dolo Diaz, PhD

SR VICE PRESIDENT - HEAD OF DEVELOPMENT SCIENCES , DENALI

CNS Drug Development: Do Biomarkers Hold the Future for Patients?

Lori Didion Hunt, BA, MBA

EXECUTIVE DIRECTOR CORPORATE AFFAIRS, ENVIRONMENTAL, SOCIAL, GOVERNANCE, AMGEN

Harnessing the Power of Biotechnology on ESG Issues

David Dodd

CHAIRMAN, CEO, GEOVAX LABS, INC

GeoVax Labs, Inc.

Smyrna, Georgia, United States

Marty Driscoll

CEO, ONCONANO MEDICINE, INC.

OncoNano Medicine, Inc.

Southlake, Texas, United States

Eric Dube, PhD

PRESIDENT & CEO, TRAVERE THERAPEUTICS, INC.

Fireside Chat: The Accelerated Approval Pathway and the Importance to Patients

San Diego, California, United States

Michael Dudley

CEO, TRANSCODE THERAPEUTICS

TransCode Therapeutics, Inc.

Boston, Massachusetts, United States

Michael Dudley, PharmD

PRESIDENT & CEO, QPEX BIOPHARMA

The Silent Pandemic: Tackling Antimicrobial Drug Resistance (AMR)

San Diego, California,

Denis Dufrane

CEO, NOVADIP BIOSCIENCES SA

Novadip Biosciences

Mont-Saint-Guibert (Corbais ), Belgium

Kristi Dula

DIRECTOR, OFFICE OF ENTREPRENEURSHIP INNOVATION & TECHNOLOGY, ILLINOIS DEPARTMENT OF COMMERCE & ECONOMIC OPPORTUNITY

Building a Strong Biomanufacturing Workforce in the United States: A Conversation with State Economic Development Experts

Frida Dunger-Johnsson

EXECUTIVE DIRECTOR, IFPA

Global Patient Advocacy – Addressing Health Inequity Across the Globe

Melissa Dupont

R&D PATIENT ENGAGEMENT LEAD, SANOFI

Partnering for Progress: Collaborating With Patient Organizations To Advance Therapy Development and Maximize Patient Benefit

Bridgewater, New Jersey, United States

Carolyn Durham, PhD

CHIEF SCIENTIFIC OFFICER, RENOVION

Renovion, Inc.

Chapel Hill, North Carolina, United States

Priyanka Dutta Passecker Sr.

DR. , HEALIVA SA

Healiva SA

Lugano, Switzerland

Jennifer Dyer

EXECUTIVE DIRECTOR, USC STEVENS CENTER FOR INNOVATION, UNIVERSITY OF SOUTHERN CALIFORNIA

The Roles of AI and Big Data in Precision Healthcare: Perspectives from the Drug Development Pathway and the Patient Journey

Los Angeles, California, United States

David Earnshaw

ASSOCIATE VICE PRESIDENT, MERCK

The big bang in pharma legislation: The European epicenter shaping global healthcare and a competitive industry

Kenilworth, New Jersey, United States

Julie Eastland, MBA, BS

PRESIDENT AND CEO, HARPOON THERAPEUTICS

How to Survive a Stormy Biotech Season: Thriving in a Challenging Market

Nevan Elam

CEO AND FOUNDER, REZOLUTE

Ending The Cycle of Chronic Disease: Leveraging New Therapeutic Approaches with Disease-Modifying Potential

Redwood City, California,

Mark Emalfarb

CHIEF EXECUTIVE OFFICER, DYADIC INTERNATIONAL, INC

Dyadic International, Inc.

Jupiter, Florida, United States

Niels Emmerich, PhD

VICE PRESIDENT, SEARCH AND EVALUATION, ABBVIE INC.

Wisdom and Wagers: Perspectives from Big Pharma Dealmakers

North Chicago, Illinois, United States

Sébastien Enault

CHIEF BUSINESS OFFICER, MEDINCELL SA

MedinCell

Jacou, France

Rafael Escandon, DrPH;MPH;PhD

PRINCIPAL, DGBI CONSULTING

Individualized Therapeutics: Walking the Line Between Research and Treatment

Bainbridge Island, Washington, United States

Amit Etkin, MD;PhD

CEO, ALTO NEUROSCIENCE INC

CNS Drug Development: Do Biomarkers Hold the Future for Patients?

Los Altos, California, United States

Jay Evans, PhD

PRESIDENT & CEO, INIMMUNE CORPORATION

Inimmune Corporation

Missoula, Montana, United States

Jeanette Evans

VP BUSINESS DEVELOPMENT, ADAPTIMMUNE

Out-License, Co-Promote, or Solo-First launch? Insights From an Expert Panel and a Decade of U.S. and EU First-Launch and Partnering Data

Oxford, United Kingdom

Stacy Feld, JD

HEAD, JOHNSON & JOHNSON INNOVATION, WEST NORTH AMERICA, AUSTRALIA & NEW ZEALAND, JOHNSON & JOHNSON

Impactful Models and Resources for De-risking and Translating University-Held Innovations

Johnson & Johnson Innovation

South San Francisco, California, United States

Agustin Fernandez III

CEO, RATIONAL VACCINES

Rational Vaccines, Inc.

Woburn, Massachusetts, United States

Brian Finrow

CO-FOUNDER & CEO, LUMEN BIOSCIENCE

Lumen Bioscience

Seattle, Washington,

Wainwright Fishburn

GLOBAL CHAIR, DIGITAL HEALTH, COOLEY

Partnering with Payors – Strategies for Success

San Diego, California,

Nasha Fitter

CEO, FOXG1 RESEARCH FOUNDATION

Female Founders: Paving the Way for Innovation and Equity

Bijean Ford

SENIOR MANAGER OF REGULATORY MEDICAL WRITING, INTERCEPT PHARMACEUTICALS

Future of Biotech

Stone mountain, Georgia, United States

Kristen Fortney, PhD

CEO, BIOAGE LABS

Development of Points to Consider: Comparability Considerations for Advanced Therapy Medicinal Products Subject to Changes in their Manufacturing Process

Richmond, California, United States

Sarah Fortt

PARTNER, LATHAM & WATKINS, LLP

Harnessing the Power of Biotechnology on ESG Issues

Austin, Texas, United States

David Foster, JD;PhD

CEO, ISLAND PHARMACEUTICALS

Island Pharmaceuticals, Ltd

Camberwell, Victoria, Australia

Kathy Francissen

HEAD OF REGULATORY, PT CELL & GENE THERAPEUTICS, GENENTECH, A MEMBER OF THE ROCHE GROUP

South San Francisco, California, United States

Cedric Francois, MD, PhD

CO-FOUNDER AND CEO/PRESIDENT, APELLIS PHARMACEUTICALS, INC

How to Survive a Stormy Biotech Season: Thriving in a Challenging Market

Waltham, Massachusetts, United States

Craig Fraser

CHIEF EXECUTIVE OFFICER & PRESIDENT, WINDTREE THERAPEUTICS, INC.

Windtree Therapeutics, Inc.

Warrington, Pennsylvania, United States

Trivia Frazier, PhD

CEO, OBATALA SCIENCES

Fostering Diversity and Bio-Equity Through Novel Financing and Training Initiatives in the Aging Innovation Ecosystem

New Orleans, Louisiana, United States

Agnete Fredriksen

CHIEF INNOVATION & STRATEGY OFFICER, NYKODE THERAPEUTICS

Defining Correlates of Protection for COVID-19: The Technology is Here, The Time is Now

Oslo, Norway

Ryan Fukushima, MBA

COO, TEMPUS

FDA's RWE Grantees: One Year On

Chicago, Illinois, United States

Maritza Gamboa

ASSOCIATE DIRECTOR, INTELLIA THERAPEUTICS

Cambridge, Massachusetts, United States

Matthew Gantz

PRESIDENT AND CEO, CASTLE CREEK BIOSCIENCES

Castle Creek Biosciences, Inc.

Exton, Pennsylvania, United States

Jorge Garces

CSO, EXACT SCIENCES CORPORATION

La Jolla, California, United States

Pat Garcia-Gonzalez, MPH

CEO, THE MAX FOUNDATION

Changing the Paradigm: Expanding Access to Oncology Medicines

Seattle, Washington, United States

Robert Garmise, PharmD

ASSOCIATE DIRECTOR, BRISTOL MYERS SQUIBB

Space & Microgravity as an Innovation Platform for R&D

New Brunswick, New Jersey, United States

Dan Gebremedhin, BS, MBA, MD

PARTNER, FLARE CAPITAL

Investors' Perspectives - Digital Health Trends and Investment Thesis in 2022 and Beyond

San Diego, California,

Nicholas Geisse

CHIEF SCIENCE OFFICER, CURI BIO

Curi Bio

Seattle, Washington,

James Geraghty

CHAIRMAN, BVGH GUESTS

Fireside Chat: A Discussion on the Orphan Drug Revolution

Boston, Massachusetts, United States

Fabian Gerlinghaus

CO-FOUNDER AND CHIEF EXECUTIVE OFFICER OF CELLARES, CELLARES

How Do We Make Cell Therapy Sustainable Long Term?

San Francisco, California,

Geno Germano

PRESIDENT & CHIEF EXECUTIVE OFFICER, ELUCIDA ONCOLOGY, INC

Elucida Oncology

Monmouth Junction, New Jersey, United States

Mathieu Ghadanfar

BUSINESS DEVELOPMENT & LICENCING OFFICER, ZIPHIUS VACCINES

Ziphius Vaccines

Merelbeke, Belgium

Anirvan Ghosh, PhD

CEO, UNITY

Ending The Cycle of Chronic Disease: Leveraging New Therapeutic Approaches with Disease-Modifying Potential

Albert Gianchetti, MBA

PRESIDENT & CEO, XYLOCOR THERAPEUTICS

XyloCor Therapeutics

Wayne, Pennsylvania, United States

Jeff Gilmore

CHIEF EXECUTIVE OFFICER, CGMPNOW

cGMPnow

Boulder, Colorado, United States

Christoph Glaetzer

CHIEF GLOBAL VALUE & ACCESS OFFICER , JANSSEN PHARMACEUTICAL COMPANIES OF J&J

Can Patient Perspectives Break Through Value Assessments That Rely on the QALY?

Titusville, New Jersey,

Jacob Glanville, PhD

FOUNDER/CEO/PRESIDENT, CENTIVAX, INC.

Centivax Inc

South San Francisco, California, United States

Joseph Gleeson, MD

RADY PROFESSOR OF NEUROSCIENCES , UCSD

Individualized Therapeutics: Walking the Line Between Research and Treatment

Dana Goldman

DEAN AND C. ERWIN AND IONE L. PIPER CHAIR, SOL PRICE SCHOOL OF PUBLIC POLICY, UNIVERSITY OF SOUTHERN CALIFORNIA

Enabling and Supporting Efficacy-Linked Pricing Contracts

Los Angeles, California,

Bruce Goldsmith

CEO, PASSAGE BIO

Gene Therapy Pioneers Discuss What's Next for Gene Therapy

Philadelphia, Pennsylvania, United States

Linda Goler Blount

PRESIDENT AND CHIEF EXECUTIVE OFFICER, BLACK WOMEN'S HEALTH IMPERATIVE

Fireside Chat: The Accelerated Approval Pathway and the Importance to Patients

Atlanta, Georgia, United States

Cecilia Gonzalo, MBA

PARTNER, OBERLAND CAPITAL MANAGEMENT

Options for Raising Capital in a Down Market

New York, New York, United States

Jennifer Good, CPA

PRESIDENT & CEO, TREVI THERAPEUTICS

Trevi Therapeutics, Inc

New Haven, Connecticut, United States

Adrian Gottschalk

PRESIDENT AND CHIEF EXECUTIVE OFFICER , FOGHORN THERAPEUTICS

From Scientific Breakthrough to Patient Impact: Bringing the Promise of Protein Degrader Therapies to Reality

Cambridge, Massachusetts,

Kiri Granger

CSO, MONUMENT THERAPEUTICS

Psychedelics: What Will It Take To Get Them to Market?

Cambridge,

Scott Gray

CEO, CLINCIERGE

Participant Sensitivity: Amplifying the Voice of the Patient in Clinical Trials

Philadelphia, Pennsylvania, United States

David Greenwald

VP, BUSINESS DEVELOPMENT, DEERFIELD

Feeding the Pipeline

Megan Grether, PhD

BD & L, BOEHRINGER INGELHEIM ANIMAL HEALTH GMBH

Boehringer Ingelheim Animal Health

Ingelheim, Germany

Anjali Gupta, PhD

BUSINESS DEVELOPMENT, AXIOM SPACE

Space & Microgravity as an Innovation Platform for R&D

San Diego, California, United States

Pam Guthrie

DIRECTOR OF CLIENT STRATEGY, CLINCIERGE

Participant Sensitivity: Amplifying the Voice of the Patient in Clinical Trials

Philadelphia, Pennsylvania, United States

Kimberly Ha

CEO, KKH ADVISORS

Next Gen Oncology Therapeutics: Changing the Cancer Landscape

New York, New York,

Todd Haim, PhD

DIRECTOR, OFFICE OF SMALL BUSINESS RESEARCH, NIA, NATIONAL INSTITUTES OF HEALTH (NIH)

Fostering Diversity and Bio-Equity Through Novel Financing and Training Initiatives in the Aging Innovation Ecosystem

Bethesda, Maryland,

Molly Harper

CHIEF BUSINESS OFFICER, SYNLOGIC

Synlogic, Inc

CAMBRIDGE, Massachusetts, United States

David Harris

PRESIDENT, INSIGHT AND MEASUREMENT

Participant Sensitivity: Amplifying the Voice of the Patient in Clinical Trials

Philadelphia, Pennsylvania, United States

Paul Hastings

PRESIDENT & CEO, NKARTA THERAPEUTICS, INC.

Fireside Chat: A Discussion on the Orphan Drug Revolution

Improving Disparity Begins with Us: Biotech Leaders Drive Diversity, Equity and Inclusion in Healthcare

South San Francisco, California, United States

Jeff Hatfield, BS

CEO, VIVIDION THERAPEUTICS

Cultivating innovation post acquisition: Bayer and Vividion’s arm’s length model

Marc Hedrick

PRESIDENT AND CEO, PLUS THERAPEUTICS

Plus Therapeutics

Austin, Texas,

James Helliwell, FRCP;MD

CEO, EUPRAXIA PHARMACEUTICALS INC.

Eupraxia Pharmaceuticals

Victoria, British Columbia, Canada

Chris Hibberd

CEO, NUCLEIX

Out-License, Co-Promote, or Solo-First launch? Insights From an Expert Panel and a Decade of U.S. and EU First-Launch and Partnering Data

San Diego, California,

Colin Hill, MS

CHIEF EXECUTIVE OFFICER, GNS HEALTHCARE

Why the FDA Will Bet More on in Silico Simulations To Trigger Better Success Rates for NDAs

Somerville, Massachusetts,

Jonathan Hirsch

INVESTOR, MULTIPLE

Artificial Intelligence and Machine Learning: Case Studies in Rare Disease Drug Development

New City, New York, United States

Steffan Ho, MD, PhD

VICE PRESIDENT AND HEAD OF TRANSLATIONAL ONCOLOGY, GLOBAL PRODUCT DEVELOPMENT, PFIZER, INC.

Why the FDA Will Bet More on in Silico Simulations To Trigger Better Success Rates for NDAs

San Diego, California, United States

Vera Hoffman

CEO, REVEAL PHARMA

Reveal Pharmaceuticals Inc

Cambridge, Massachusetts, United States

Dorothy Hoffman, MPP

EXTERNAL ENGAGEMENT LEAD, HEALTHCARE INNOVATION CENTER, PFIZER

Value-Based Pledge (VBP): Patients at the Center of Value-Based Arrangements With Manufacturers

New York, New York, United States

Beth Hoffman

CEO & FOUNDER, ORIGAMI THERAPEUTICS, INC.

Origami Therapeutics

San Diego, California, United States

Ben Hohn, MBA

PRINCIPAL -- BD, PIPELINE AND LAUNCH STRATEGY & EMERGING PHARMA LEAD, ZS ASSOCIATES

Princeton, New Jersey, United States

Michele Holcomb, PhD

EVP, CHIEF STRATEGY AND BUSINESS DEVELOPMENT OFFICER, CARDINAL HEALTH

Value-Based Pledge (VBP): Patients at the Center of Value-Based Arrangements With Manufacturers

Dublin, Ohio, United States

Thomas Hoover

CHIEF BUSINESS OFFICER, MATINAS BIOPHARMA, INC.

Matinas Biopharma

Concord, Massachusetts, United States

Danielle Horowitz, CIC;MBA

AVP, SENIOR LIFE SCIENCE SPECIALIST, CHUBB

Chubb

Alpharetta, Georgia, United States

Paul Howard, PhD

SENIOR DIRECTOR OF PUBLIC POLICY, AMICUS THERAPEUTICS, INC.

Artificial Intelligence and Machine Learning: Case Studies in Rare Disease Drug Development

Philadelphia, Pennsylvania, United States

Dar-Jen Hsieh, PhD

CEO, TAIWAN PAVILION

ACRO Biomedical Co., Ltd.

Kaohsiung City, Taiwan

Wei Chiao Huang

DIRECTOR, VACCINE DEVELOPMENT, POP BIOTECHNOLOGIES

POP Biotechnologies

Buffalo, New York,

Richard Hughes IV, JD, MPH

FORMER VICE PRESIDENT, PUBLIC POLICY AT MODERNA, EPSTEIN BECKER & GREEN

Vaccine Innovation and the Future of Life-Course Immunization

Washington, United States

Phillip Hulley

VICE PRESIDENT PLANNING AND PROCUREMENT , AVANTOR

Supply chain crisis– forward looking solutions

Brenda Huneycutt

DIRECTOR, GLOBAL REGULATORY POLICY, MERCK

COVID-19 360°: Embedding Global Best Practices in Routine Regulatory Action and Preparing for the Next Pandemic

Rockville, Maryland, United States

Melissa Hunt

, HEALTH CANADA

Glenn Hunzinger

PARTNER, PRICEWATERHOUSECOOPERS, LLP

Wisdom and Wagers: Perspectives from Big Pharma Dealmakers

New York, New York, United States

Albert Hwang

MANAGING DIRECTOR, MORGAN STANLEY

Realizing the Promise of Gene Therapy: Current Challenges, Opportunities and Trends

New York, New York, United States

Jangyoun Hwang, PhD

TEAM MANAGER, FUTURE MEDICINE CO., LTD.

Future Medicine Co., Ltd.

Seongnam, Korea, Republic of

Melanie Igwe

CO-FOUNDER AND COO, DRUG VIU

Solving the Founder/Funder Conundrum to Drive Health Equity and Support Marginalized Communities

Haras Ikam

Smaki Test - Edited!

Sin-Hyeog Im

CEO, IMMUNOBIOME

ImmunoBiome

Pohang,

Cynthia Isaac, PhD

MANAGING DIRECTOR, CORPORATE COMMUNICATIONS PRACTICE, SYNEOS HEALTH

Solving the Founder/Funder Conundrum to Drive Health Equity and Support Marginalized Communities

New York, New York,

Catriona Jamieson, MD, PhD

DIRECTOR, SANFORD STEM CELL CLINICAL CENTER; DIRECTOR, CIRM ALPHA STEM CELL CLINIC; CHIEF, DIVISION, UNIVERSITY OF CALIFORNIA, SAN DIEGO AND ASPERA BIOMEDICINES

Space & Microgravity as an Innovation Platform for R&D

Shreya Jani

VICE PRESIDENT, HEAD OF CORPORATE AFFAIRS, BEIGENE

Changing the Paradigm: Expanding Access to Oncology Medicines

Manhasset, New York, United States

Jana Jensen

CHIEF OPERATING OFFICER, 3DC, DEERFIELD MANAGEMENT COMPANY LP

Impactful Models and Resources for De-risking and Translating University-Held Innovations

New York City, New Jersey, United States

Pavle Jeremic

CEO, AETHER BIOMACHINES, INC.

Aether Bio

Menlo Park, California, United States

Allison Jeynes-Ellis

CHIEF EXECUTIVE OFFICER, AVILLION LLP

Avillion LLP

Uxbridge, United Kingdom

Charley John, PharmD

DIRECTOR, U.S. PUBLIC POLICY , WALGREENS

Vaccine Innovation and the Future of Life-Course Immunization

Washington, District of Columbia, United States

Stefanie Johns

CHIEF SCIENTIFIC OFFICER, HOTH THERAPEUTICS, INC.

Hoth Therapeutics, Inc

New York, New York, United States

Russell Jones, CPA

PARTNER, DELOITTE

Protecting Your Global Assets

San Francisco, California, United States

Alex Jung

PRINCIPAL, ERNST & YOUNG, LLP

Value-Based Pledge (VBP): Patients at the Center of Value-Based Arrangements With Manufacturers

Chicago, Illinois,

David Kabakoff, PhD, BA

EXECUTIVE PARTNER, SOFINNOVA INVESTMENTS

Next Gen Oncology Therapeutics: Changing the Cancer Landscape

La Jolla, California, United States

Sanjay Kakkar

PRESIDENT & CEO, TRANQUIS THERAPEUTICS

Tranquis

Redwood City, California, United States

Mahesh Karande

PRESIDENT & CEO, OMEGA THERAPEUTICS

Advancing and Commercializing Longevity Market Innovations — Leveraging Seed Funding, Foundational, and Accelerator Support To Advance Innovations for Older Adults

Vik Kashyap, BA

CEO & FOUNDER, TOI LABS

San Francisco, California,

Konstantina Katcheves, MS, JD, BS

SENIOR VICE PRESIDENT, STRATEGY & BUSINESS DEVELOPMENT, BRISTOL MYERS SQUIBB

Navigating Asia-Pacific Innovation Deal Opportunities

What Happens When Your AI Identifies the Next Big Drug Candidate? Filing for a Patent May Not Be It.

Ellicott City, Maryland, United States

Syed Kazmi, MBA;PhD

PRESIDENT & CHIEF EXECUTIVE OFFICER, JUBILANT THERAPEUTICS, INC.

Trends, Challenges and Opportunities of Epigenetic Therapeutics in Cancer

Bedminster, New Jersey, United States

Kenneth Kehl

MD, MPH, DANA-FARBER CANCER INSTITUTE

AACR Project GENIE: Powering Precision Medicine Through an International Consortium and a Pre-Competitive Collaboration With the Biopharmaceutical Industry

Wellesley Hills, Massachusetts, United States

Hans Keirstead

CHAIRMAN & CEO, AIVITA BIOMEDICAL, INC.

AIVITA Biomedical, Inc.

Irvine, California, United States

Tsipi Keren-Lehrer, BSc, LLB

HEAD OF BUSINESS DEVELOPMENT AND STRATEGIC ADVISOR, BIOLINERX, LTD

Out-License, Co-Promote, or Solo-First launch? Insights From an Expert Panel and a Decade of U.S. and EU First-Launch and Partnering Data

Modi'in, Israel

Danielle Kerkovich

DIRECTOR OF RESEARCH DEVELOPMENT AND PARTNERSHIPS, INTERNATIONAL FOP ASSOCIATION (IFOPA)

Partnering for Progress: Collaborating With Patient Organizations To Advance Therapy Development and Maximize Patient Benefit

North Kansas City, Missouri,

Randolf Kerschbaumer

CEO, ONCOONE

OncoOne

Klosterneuburg, Austria

John Kerwin

TECHNICAL HEAD OF RESILIENCE’S GENE THERAPY FRANCHISE, RESILIENCE

Current Realities of Make vs. Buy For Advanced Therapies in Manufacturing

Anjalee Khemlani

SENIOR REPORTER, YAHOO FINANCE

None of Us are Safe Unless All of Us are Safe: Business Lessons Learned Delivering a Global COVID-19 Vaccine

New York, New York, United States

Sarah Kilpatrick, MBA

BUSINESS DEVELOPMENT GROUP LEAD, INTERNAL MEDICINE AND VACCINES, PFIZER

Wisdom and Wagers: Perspectives from Big Pharma Dealmakers

Helen Kim, PhD

EXECUTIVE DIRECTOR, EXTERNAL R&D, AMGEN INC.

Amgen Inc.

Thousand Oaks, California, United States

Yongchan Kim

FOUNDER AND CEO, TERAIMMUNE, INC.

TeraImmune, Inc.

Gaithersburg, Maryland,

Donald Kohn, MD

PROFESSOR, UNIVERSITY OF CALIFORNIA, LOS ANGELES

Gene Therapy Pioneers Discuss What's Next for Gene Therapy

Safety Aspects of AAV- and Lentivirus-based Cell and Gene Therapy

Los Angeles, California,

Neal Koller

CHAIRMAN & CEO, ALPHYN BIOLOGICS, LLC

Alphyn Biologics, Inc.

Annapolis, Maryland, United States

Anja Krammer

CHIEF EXECUTIVE OFFICER, THERAPEUTIC HUMAN POLYCLONALS, INC

Turn Biotechnologies

San Francisco, California, United States

Arthur Kuan

CEO, CG ONCOLOGY, INC.

Next Gen Oncology Therapeutics: Changing the Cancer Landscape

Irvine, California, United States

Yoshi Kumagai

PRESIDENT AND CEO, ORTHOTROPHIX, INC.

OrthoTrophix, Inc.

Foster City, California, United States

Seema Kumar

GLOBAL HEAD, OFFICE OF INNOVATION, JOHNSON & JOHNSON

Future of Biotech

Darius Lakdawalla, PhD

QUINTILES CHAIR IN PHARMA DEV & REG INNOVATION, UNIVERSITY OF SOUTHERN CALIFORNIA

Enabling and Supporting Efficacy-Linked Pricing Contracts

Los Angeles, California, United States

Jordan Lancaster, PhD

CHIEF EXECUTIVE OFFICER, AVERY THERAPEUTICS, INC.

Avery Therapeutics, Inc.

Tucson, Arizona, United States

Pepper Landson

CO-FOUNDER / CEO, PRAETEGO, INC.

Praetego Inc

Durham, North Carolina, United States

Mark Lappe

CHIEF EXECUTIVE OFFICER, INHIBRX

Navigating an IPO: Are Crossover Rounds Still Needed To Make a Deal Float?

La Jolla, California, United States

Camille Laturno

VICE PRESIDENT, COMMERCIAL & CHIEF PRIVACY OFFICER, GLOBAL BLOOD THERAPEUTICS

Is This the End of Global Clinical Trials? What You Need to Know To Navigate the Complex Data Privacy and National Security Restrictions Across International Markets from Europe to China

South San Francisco, California, United States

Donna LaVoie

PRESIDENT & CEO, LAVOIEHEALTHSCIENCE

How to Tell Your Story in 15 Slides

Boston, Massachusetts, United States

Jittrakul Leartsakulpanitch

VP, GLOBAL MARKET ACCESS & ANALYTICS, JOHNSON & JOHNSON

Titusville, New Jersey,

Seth Lederman, MD

CHIEF EXECUTIVE OFFICER, TONIX PHARMACEUTICALS, INC

Tonix Pharmaceuticals

Chatham, New Jersey, United States

JayJay Lee

CEO, FATIABGEN CO., LTD.

Fatiabgen Bioscience Korea

Sejong, Korea, Republic of

Hongwon Lee

CTO, PROTEINA CO., LTD.

PROTEINA Co., Ltd.

Seoul, Korea, Republic of

Sang Hoon Lee, PhD, BS, MS

CEO/FOUNDER, ABL BIO

Navigating Asia-Pacific Innovation Deal Opportunities

Pangyo,

Julianna LeMieux, PhD

SENIOR SCIENCE WRITER FOR GENETIC ENGINEERING & BIOTECHNOLOGY NEWS , GEN

A New Era in Gene Therapy

Rachael Lester, MBA

SVP, BUSINESS DEVELOPMENT & CORPORATE STRATEGY, HARPOON THERAPEUTICS

Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking

South San Francisco, California, United States

Melanie Levy

MEMBER, MINTZ, LEVIN, COHN, FERRIS, GLOVSKY & POPEO, PC

Navigating an IPO: Are Crossover Rounds Still Needed To Make a Deal Float?

Boston, Massachusetts, United States

Ji Li, PhD

PRESIDENT, AFFAMED THERAPEUTICS

Navigating Asia-Pacific Innovation Deal Opportunities

New York, New York, United States

Lily Li, PhD

PRINCIPAL, NORTHPOND VENTURES

Persuasive Pitching – Do You Have the Talent to Engage Investors?

Cambridge, Massachusetts, United States

Ivan Liachko, PhD

CEO, PHASE GENOMICS, INC.

Phase Genomics, Inc.

Seattle, Washington, United States

Han Lim

VP OF BUSINESS OPERATIONS, DEEPCURE

DeepCure

Berkeley, California, United States

Robert Lindberg, PhD

VICE PRESIDENT, SCIENCE & TECHNOLOGY, NORTH CAROLINA BIOTECHNOLOGY CENTER

Impactful Models and Resources for De-risking and Translating University-Held Innovations

Research Triangle, North Carolina, United States

Jason Litten

FORMER CMO ARTIVA BIOTHERAPEUTICS, ARTIVA BIOTHERAPEUTICS

Which Shots, What Goal, and Who Should Shoot? Developing a Sustainable Portfolio for Gene Therapy and Genome Editing Platforms

Amy Liu

INVESTOR, MUBADALA CAPITAL- VENTURES

Faster and Stronger: How RNA Will Advance Precision Medicine and Accessibility

San Francisco, California, United States

Donald Lo, PhD

DIRECTOR, THERAPEUTIC DEVELOPMENT BRANCH, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS)

Impactful Models and Resources for De-risking and Translating University-Held Innovations

Rockville, Maryland,

Ilise Lombardo

CHIEF MEDICAL OFFICER, KRIYA THERAPEUTICS

Ending The Cycle of Chronic Disease: Leveraging New Therapeutic Approaches with Disease-Modifying Potential

San Francisco, California,

Henry W. Long, PhD, BS

SCIENTIFIC DIRECTOR, CENTER FOR FUNCTIONAL CANCER EPIGENETICS, DANA-FARBER CANCER INSTITUTE

Trends, Challenges and Opportunities of Epigenetic Therapeutics in Cancer

Kip Ludwig

ASSOCIATE PROFESSOR, UNIVERSITY OF WISCONSIN - MADISON

Madison, Wisconsin, United States

Barbara Lueckel

GLOBAL HEAD, TECHNOLOGY PARTNERING, ROCHE

Maximizing the Potential of Platforms Through Creative and Effective Deal-Making Strategies

Basel, Switzerland

Greg Lyles

VICE PRESIDENT OF MARKET ACCESS, AKILI INTERACTIVE

Understanding the Reimbursement Landscape for Prescription Digital Therapeutics

Philadelphia, Pennsylvania,

M. Joe Ma

CEO, PAPIVAX

PapiVax Biotech, Inc.

Taipei City, Taiwan

Douglas MacDougall

MANAGING PARTNER, MACDOUGALL

Persuasive Pitching – Do You Have the Talent to Engage Investors?

Natick, Massachusetts,

Olivier Madec

GLOBAL HEAD OF M&A AND VENTURE INVESTMENTS, SERVIER EUROPE

Servier

Suresnes cedex, Ile-de-France, France

Leonardo Magneschi, PhD

HEAD OF MOLECULAR BIOLOGY, INGENZA LTD

Ingenza Ltd.

Edinburgh, United Kingdom

Lawrence Mahan, PhD

PRESIDENT, THE BIOTECHNOLOGY INSTITUTE

Future of Biotech

Washington, United States

Nadir Mahmood, PhD

CHIEF FINANCIAL AND BUSINESS OFFICER, NKARTA THERAPEUTICS, INC.

How to Survive a Stormy Biotech Season: Thriving in a Challenging Market

South San Francisco, California, United States

Abdullah Mahmud

EXECUTIVE CHAIRMAN, HA TECH PTY LTD

HA TECH PTY LTD

Sydney, New South Wales, Australia

Morena Makhoana

CEO, BIOVAC

Building Vaccine Manufacturing Capacity in Africa

Joan Mannick

HEAD OF R&D, LIFE BIOSCIENCES

Cambridge, Massachusetts,

Adam Margolin

CEO, NEXTVIVO

NextVivo

Palo Alto, California, United States

Ross Margulies

PARTNER, FOLEY HOAG LLP

Understanding the Reimbursement Landscape for Prescription Digital Therapeutics

Washington, District of Columbia, United States

Sabrina Martucci Johnson

PRESIDENT & CEO, DARé BIOSCIENCE

Daré Bioscience

San Diego, California, United States

Neal Masia

CO-FOUNDER, ENTITYRISK, INC.

Enabling and Supporting Efficacy-Linked Pricing Contracts

Princeton, New Jersey,

Kelly Maynard

PRESIDENT AND FOUNDER, LITTLE HERCULES FOUNDATION

Female Founders: Paving the Way for Innovation and Equity

Dublin, Ohio, United States

Charlie McDermott

CHAIRMAN AND CEO, PRIMMUNE THERAPEUTICS

Primmune Therapeutics

Carlsbad, California, United States

Patrice McNicoll

CO-HEAD INVESTMENT BANKING, B. RILEY SECURITIES, INC.

Navigating an IPO: Are Crossover Rounds Still Needed To Make a Deal Float?

Jessica Mega, MD, MPH

CO-FOUNDER AND CHIEF MEDICAL & SCIENTIFIC OFFICER, VERILY

Fireside Chat with Jessica Mega, Chief Medical & Scientific Officer, Co-founder, Verily

Scott Megaffin

CEO, ADISO THERAPEUTICS

Adiso Therapeutics

Concord, Massachusetts, United States

Amit Mehta

VP, HEAD OF BUSINESS DEVELOPMENT, GENENTECH RESEARCH & EARLY DEVELOPMENT, GENENTECH

Genentech

South San Francisco, California,

Pete Meinke, PhD

, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE

Feeding the Pipeline

New York, New York, United States

Gustavo Mendes Lima Santos

HEAD OF GENERAL OFFICE OF MEDICINES AND BIOLOGICAL PRODUCTS, AGêNCIA NACIONAL DE VIGILâNCIA SANITáRIA – ANVISA

AACR Project GENIE: Powering Precision Medicine Through an International Consortium and a Pre-Competitive Collaboration With the Biopharmaceutical Industry

Quentin Messer

CEO, MICHIGAN ECONOMIC DEVELOPMENT CORPORATION

Building a Strong Biomanufacturing Workforce in the United States: A Conversation with State Economic Development Experts

Lansing, Michigan, United States

Daniel Meyer

CEO, CELLCHORUS, LLC

CellChorus

Houston, Texas, United States

Christine Micheel, PhD, PMP

RESEARCH ASSISTANT PROFESSOR, DEPARTMENT OF MEDICINE, DIVISION OF HEMATOLOGY/ONCOLOGY; PORTFOLIO MANAGER, PRECISION ONCOLOGY INITIATIVES, VANDERBILT-INGRAM CANCER CENTER, VANDERBILT UNIVERSITY MEDICAL CENTER

Nashville, Tennessee, United States

Tim Miller, PhD

CEO, PRESIDENT, AND CO-FOUNDER, FORGE BIOLOGICS

Forge Biologics

Grove City, Ohio,

Sanjay Mistry, PhD

VICE PRESIDENT OF JOHNSON & JOHNSON INNOVATION, HEAD NEW VENTURES, JNJ

Investors' Perspectives - Digital Health Trends and Investment Thesis in 2022 and Beyond

Persuasive Pitching – Do You Have the Talent to Engage Investors?

San Diego, California,

Ryan Mitchell, PhD

DIRECTOR BUSINESS DEVELOPMENT, SATELLOS BIOSCIENCE INC.

Satellos Bioscience Inc.

Toronto, Ontario, Canada

Emily Mitchell

EXECUTIVE DIRECTOR, DECENTRALIZED CLINICAL TRIAL OPERATIONS, ICON

How Digital Health Technical Innovation is Driving Decentralized Clinical Trial Success

Wilmington, Delaware,

Daria Mochly-Rosen, PhD

THE GEORGE D. SMITH PROFESSOR IN TRANSLATIONAL MEDICINE, CHEMICAL AND SYSTEMS BIOLOGY, STANFORD UNIVERSITY

Feeding the Pipeline

Stanford, California, United States

James Moe

PRESIDENT, OLIGOMERIX, INC.

Oligomerix, Inc

White Plains, New York,

Tamer Mohamed

CEO, ASPECT BIOSYSTEMS

Aspect Biosystems

Vancouver, British Columbia, Canada

Andy Molnar

CEO, DIGITAL THERAPEUTICS ALLIANCE

Understanding the Reimbursement Landscape for Prescription Digital Therapeutics

Arlington, Virginia, United States

Remo Moomiaie-Qajar, MD

CEO, CYTONUS THERAPEUTICS, INC.

Cytonus Therapeutics

Carlsbad, California, United States

Rashad Morgan, JD

PARTNER, CROWELL & MORING LLP

What Happens When Your AI Identifies the Next Big Drug Candidate? Filing for a Patent May Not Be It.

Chicago, Illinois, United States

Rick Morris

SVP TECHNOLOGY BIOTECH, PALL CORPORATION

Current Realities of Make vs. Buy For Advanced Therapies in Manufacturing

Westborough, Massachusetts,

Dee Dee Myers

DIRECTOR, CA GOVERNOR’S OFFICE OF BUSINESS & ECONOMIC DEVELOPMENT

Building a Strong Biomanufacturing Workforce in the United States: A Conversation with State Economic Development Experts

Elizabeth Naldi-Jacob

VICE PRESIDENT, BUSINESS DEVELOPMENT & LICENSING; HEAD, ONCOLOGY BUSINESS DEVELOPMENT & HEADQUARTERS TRANSACTIONS, MERCK

Wisdom and Wagers: Perspectives from Big Pharma Dealmakers

Kenilworth, New Jersey, United States

Sai Nandi

CBO, ORYZON GENOMICS, S.A.

Oryzon Genomics SA

Barcelona, Spain

Paul Neureiter

EXECUTIVE DIRECTOR FOR INTERNATIONAL GOVERNMENT AFFAIRS AND TRADE POLICY, AMGEN INC.

Is This the End of Global Clinical Trials? What You Need to Know To Navigate the Complex Data Privacy and National Security Restrictions Across International Markets from Europe to China

Washington, District Of Columbia,

Diem Nguyen

CHIEF EXECUTIVE OFFICER, XALUD THERAPEUTICS, INC.

Which Shots, What Goal, and Who Should Shoot? Developing a Sustainable Portfolio for Gene Therapy and Genome Editing Platforms

A New Era in Gene Therapy

New York, New York, United States

Karoly Nikolich

PARTNER, PIVOTAL BIOVENTURE PARTNERS

San Francisco, California, United States

Don O'Sullivan, MBA;PhD

MR., ASHER BIOTHERAPEUTICS, INC

Asher Biotherapeutics

South San Francisco, California, United States

Joshua Ofman, MD

PRESIDENT AND CHIEF MEDICAL OFFICER, GRAIL

AACR Project GENIE: Powering Precision Medicine Through an International Consortium and a Pre-Competitive Collaboration With the Biopharmaceutical Industry

Tim Oldham, PhD

CEO AND MANAGING DIRECTOR, ADALTA PTY LTD.

AdAlta Ltd

Bundoora, Australia

Kevin Oliver

SVP, HEAD OF GLOBAL BD, SIMCERE PHARMACEUTICAL

Simcere Pharmaceutical

Cambridge, Massachusetts, United States

Uche Orji

CEO, NIGERIA SOVEREIGN INVESTMENT AUTHORITY

Investing in Vaccine Manufacturing Capacity in Africa

Samir Ounzain, PhD

CEO & SCIENTIFIC CO-FOUNDER, HAYA THERAPEUTICS

Faster and Stronger: How RNA Will Advance Precision Medicine and Accessibility

Epalinges, Switzerland

David Oxley

PRESIDENT-INTERNATIONAL, EXOPHARM LTD

Exopharm, Ltd.

Melbourne, Australia

Janak Padia, PhD

PRESIDENT & CEO, PRIMETIME LIFE SCIENCES LLC

Primetime Life Sciences, LLC

Germantown, Maryland, United States

Vaithianathan Palaniappan

CHIEF SCIENTIFIC OFFICER, PIONEERING MEDICINES VII, INC

Safety Aspects of AAV- and Lentivirus-based Cell and Gene Therapy

Cambridge, Massachusetts, United States

Joel Papernik, Esq

MEMBER, MINTZ, LEVIN, COHN, FERRIS, GLOVSKY & POPEO, PC

Utilizing an Existing SPAC To Take Your Private Biotech Company Public

New York, New York, United States

Bhash Parasuraman

VICE PRESIDENT, PFIZER INC.

Enabling and Supporting Efficacy-Linked Pricing Contracts

Collegeville, Pennsylvania,

Anand Parikh

CO-FOUNDER AND CEO, FAETH THERAPEUTICS, INC.

Next Gen Oncology Therapeutics: Changing the Cancer Landscape

San Francisco, California, United States

Jung-Hwan Park

CTO, QUADMEDICINE, INC.

QuadMedicine, Inc.

Sungnam-si, Gyeonggi-do, South Korea,

Sung Soo Park

ASSOCIATE MANAGER, NEXEL CO., LTD.

NEXEL

Seoul,

Michael Paskow, MPH

ASSOCIATE DIRECTOR, EPIDEMIOLOGY, ASTRAZENECA

Gaithersburg, Maryland, United States

Kal Patel, MD

CEO & CO-FOUNDER, BRIGHTINSIGHT

Partnering with Payors – Strategies for Success

BrightInsight

San Jose, California, United States

Steve Paul

CHAIRMAN OF THE BOARD, PRESIDENT, AND CEO, KARUNA THERAPEUTICS

Neuropsychiatric Innovation and Fighting Stigma in Mental Health—Fireside Chat with Dr. Steve Paul, Karuna Therapeutics

Thomas Paul

SENIOR DIRECTOR, PFIZER LA JOLLA LABORATORIES

Trends, Challenges and Opportunities of Epigenetic Therapeutics in Cancer

San Diego, California, United States

Angelica Peebles

REPORTER, BLOOMBERG NEWS

From Scientific Breakthrough to Patient Impact: Bringing the Promise of Protein Degrader Therapies to Reality

New York, New York, United States

Pete Pellerito

SENIOR POLICY ADVISER, BIO

Building a Strong Biomanufacturing Workforce in the United States: A Conversation with State Economic Development Experts

David Peloquin

SENIOR ADVISOR, MULTI-REGIONAL CLINICAL TRIAL CENTER OF BRIGHAM AND WOMEN’S HOSPITAL AND HARVARD; PARTNER, ROPES & GRAY, ROPES & GRAY

Is This the End of Global Clinical Trials? What You Need to Know To Navigate the Complex Data Privacy and National Security Restrictions Across International Markets from Europe to China

John Pennett

PARTNER, EISNERAMPER

Utilizing an Existing SPAC To Take Your Private Biotech Company Public

Iselin, New Jersey, United States

Rob Perez

OPERATING PARTNER, GENERAL ATLANTIC

Improving Disparity Begins with Us: Biotech Leaders Drive Diversity, Equity and Inclusion in Healthcare

Omar Perez

HEAD OF MEDICAL DIAGNOSTICS, US MEDICAL AFFAIRS ONCOLOGY, ASTRAZENECA

Challenges in Implementing Personalized Medicine in Clinical Practice

Washington,

Glenn Phillips, PhD

GLOBAL HEAD HEOR, ARGENX

Can Patient Perspectives Break Through Value Assessments That Rely on the QALY?

Boston, Massachusetts, United States

Corey Phillips

ASSOCIATE DIRECTOR DIVERSITY RECRUITMENT , ABBVIE

Development of Points to Consider: Comparability Considerations for Advanced Therapy Medicinal Products Subject to Changes in their Manufacturing Process

Anna Lisa Picciolo-Lehrke, PhD

HEAD OF BUSINESS DEVELOPMENT NEUROLOGY, UCB SA

Joining forces to accelerate innovation in neuroscience

Monheim, Germany

Karin Pihel, RAC, PhD

SR. DIRECTOR, CMC REGULATORY AFFAIRS , ENZYVANT THERAPEUTICS

Rupa Pike

SR DIRECTOR, R&D PROJECTS, THERMO FISHER SCIENTIFIC

Current Realities of Make vs. Buy For Advanced Therapies in Manufacturing

Fountain Hills, Arizona, United States

Smita Pillai

CHIEF DIVERSITY, EQUITY & INCLUSION OFFICER , REGENERON

AACR Project GENIE: Powering Precision Medicine Through an International Consortium and a Pre-Competitive Collaboration With the Biopharmaceutical Industry

Mathew Pletcher

SENIOR VICE PRESIDENT AND DIVISION HEAD OF GENE THERAPY RESEARCH AND TECHNICAL OPERATIONS, ASTELLAS GENE THERAPIES

A New Era in Gene Therapy

San Francisco, California,

Erica Plybeah

FOUNDER AND CEO, MEDHAUL

Solving the Founder/Funder Conundrum to Drive Health Equity and Support Marginalized Communities

Christopher Porter

VICE PRESIDENT, GOVERNMENT AFFAIRS AND POLICY, TRAVERE THERAPEUTICS, INC.

Modernizing Newborn Screening: High Patient Impact, Big Challenges

San Diego, California, United States

Steven Potts

COFOUNDER & CEO, ONCOMYX THERAPEUTICS

OncoMyx Therapeutics

Phoenix, Arizona, United States

Cody Powers

PRINCIPAL, ZS ASSOCIATES

How Do We Make Cell Therapy Sustainable Long Term?

New York, New York,

Daryl Pritchard, PhD

VICE PRESIDENT, SCIENCE POLICY, PERSONALIZED MEDICINE COALITION

Challenges in Implementing Personalized Medicine in Clinical Practice

Washington, District of Columbia, United States

Emmet Purtill, MBA

VICE PRESIDENT BUSINESS DEVELEPMENT, NICOX, SA

Nicox

Valbonne, France

John Quackenbush

PROFESSOR, COMPUTATIONAL BIOLOGY AND CHAIR, DEPARTMENT OF BIOSTATISTICS, HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH

Why the FDA Will Bet More on in Silico Simulations To Trigger Better Success Rates for NDAs

Marco Quarta

CEO, RUBEDO LIFE SCIENCES

Rubedo Life Sciences

Sunnyvale, California, United States

Jeff Rabkin

PARTNER, JONES DAY

Protecting Your Global Assets

Karma Rabon-Stith, PhD

SENIOR DIRECTOR, RWE SCIENTIST ONCOLOGY TEAM LEAD, PFIZER

Gaithersburg, Maryland, United States

Susan Raiola

PRESIDENT, REAL ENDPOINTS

Value-Based Pledge (VBP): Patients at the Center of Value-Based Arrangements With Manufacturers

Florham Park, New Jersey,

Karthik Ramachandran, PhD

CHIEF OPERATING OFFICER, LIKARDA, LLC

Likarda, LLC

Cambridge, Massachusetts, United States

Shankar Ramaswamy

CEO, KRIYA THERAPEUTICS

A New Era in Gene Therapy

San Francisco, California,

John Ramunas, PhD

CHIEF EXECUTIVE OFFICER, REJUVENATION TECHNOLOGIES

Rejuvenation Technologies Inc.

Mountain View, California, United States

Kyle Rand, BA

CEO & COFOUNDER, RENDEVER

Advancing and Commercializing Longevity Market Innovations — Leveraging Seed Funding, Foundational, and Accelerator Support To Advance Innovations for Older Adults

Somerville, Massachusetts,

Araz Raoof

PRESIDENT FRI & SVP GLOBAL DRUG DISCOVERY & EXTERNAL INNOVATION, FERRING INTERNATIONAL CENTER S.A.

Ferring Research Institute

St-Prex, Vaud, Switzerland

Kurt Rasmussen, PhD

CHIEF SCIENTIFIC OFFICER, DELIX THERAPEUTICS, INC.

Psychedelics: What Will It Take To Get Them to Market?

Rockville, Maryland, United States

Deborah Rathjen, PhD

MANAGING DIRECTOR AND CEO, CARINA BIOTECH

Carina Biotech

Mawson Lakes, South Australia, Australia

Saroj Regmi, PhD

HEALTH SCIENTIST ADMINISTRATOR, NATIONAL INSTITUTES OF HEALTH (NIH)

Advancing and Commercializing Longevity Market Innovations — Leveraging Seed Funding, Foundational, and Accelerator Support To Advance Innovations for Older Adults

Bethesda, Maryland, United States

Christina Reisinger

VICE PRESIDENT, RISK MANAGEMENT, LABCORP DRUG DEVELOPMENT

Limiting what could be Limitless: Minimizing risk through effective business contingency planning

Princeton, New Jersey, United States

Paul Rennie

CEO, PARADIGM BIOPHARMACEUTICALS, PARADIGM BIOPHARMACEUTICALS

Paradigm Biopharmaceuticals

Melbourne, Victoria,

Michael Retterath

CHIEF BUSINESS OFFICER, SPARK THERAPEUTICS, INC.

Which Shots, What Goal, and Who Should Shoot? Developing a Sustainable Portfolio for Gene Therapy and Genome Editing Platforms

philadelphia, Pennsylvania, United States

Carolyn Reynolds

CO-FOUNDER, PANDEMIC ACTION NETWORK

Getting to 100 Days: Driving Vaccine Innovation Between Pandemics

Paul Richardson

SENIOR DIRECTOR CONSULTING, THREAD RESEARCH

How Digital Health Technical Innovation is Driving Decentralized Clinical Trial Success

Tustin, California,

Julian Ritchey

HEAD OF US VACCINE PUBLIC AFFAIRS AND ADVOCACY, SANOFI

Advancing and Commercializing Longevity Market Innovations — Leveraging Seed Funding, Foundational, and Accelerator Support To Advance Innovations for Older Adults

Allentown, Pennsylvania,

Richard Roden

PROFESSOR, PAPIVAX

Up Therapeutics LLC

Baltimore, Maryland, United States

Isaac Rodriquez-Chavez, PhD, MHS

SENIOR VICE PRESIDENT, SCIENTIFIC AND CLINICAL AFFAIRS, ICON PLC.

How Digital Health Technical Innovation is Driving Decentralized Clinical Trial Success

Charlottesville, Virginia,

Sheri Rose, BA;MEd

CEO, THRIVE CENTER, INC.

Louisville, Kentucky, United States

Thomas Rossi

CHIEF EXECUTIVE OFFICER, VENTHERA, INC.

Venthera, Inc.

Portsmouth, New Hampshire,

Bill Rote

SENIOR VICE PRESIDENT OF RESEARCH AND DEVELOPMENT, TRAVERE THERAPEUTICS

New Regulatory Policies Creating Opportunities and Considerations for Development Programs

Eric Rowinsky

CHIEF MEDICAL OFFICER, HUMMINGBIRD BIOSCIENCE

Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking

Boca Raton, Florida,

Sid Roychoudhury, PhD

PROGRAM STRATEGY LEADER , GILEAD SCIENCES

Why the FDA Will Bet More on in Silico Simulations To Trigger Better Success Rates for NDAs

Susan Ruediger

CHIEF MISSION OFFICER, CMT RESEARCH FOUNDATION

Partnering for Progress: Collaborating With Patient Organizations To Advance Therapy Development and Maximize Patient Benefit

Atlanta, Georgia, United States

Inez Ruiz-White, PhD

R&D DE&I LEAD, OTSUKA PHARMACEUTICALS

Equity by Design: Utility of a Metrics Framework and Metrics To Evaluate Progress on Diversity, Equity, and Inclusion in Clinical Research

Princeton, New Jersey, United States

Renee Ryan

CEO, CALA HEALTH

San Mateo, California,

James Sahn, PhD

VICE PRESIDENT OF DRUG DEVELOPMENT, 4E THERAPEUTICS

4E Therapeutics

Austin, Texas, United States

Mansoor Saleh, MD

FOUNDING DIRECTOR, CANCER CENTER, AGA KHAN UNIVERSITY

Cancer Trials Don’t Have To Fail 90% of the Time. Seriously.

Nairobi,

Daniel Saltzman, PhD, MD

CHIEF OF PEDIATRIC SURGERY (U OF MN MED SCHOOL); CHIEF MEDICAL OFFICER (SALSPERA), UNIVERSITY OF MINNESOTA MEDICAL SCHOOL; SALSPERA

Salspera

Oakdale, Minnesota,

Stephen Sammut, MBA;PhD

SENIOR FELLOW, UNIVERSITY OF PENNSYLVANIA, CENTER FOR TECHNOLOGY TRANSFER

Achieving Global Health Equity with BioPharma and Medtech

Wynnewood, Pennsylvania, United States

Veronica Sandoval

PRINCIPAL, PATIENT INCLUSION & HEALTH EQUITY, GENENTECH

Best Practices for Building an Inclusive Biotech Company

James Sapirstein

CHAIRMAN, PRESIDENT & CEO, FIRST WAVE BIOPHARMA, INC.

First Wave BioPharma, Inc.

Boca Raton, Florida, United States

Niranjan Sardesai

CEO, GENEOS THERAPEUTICS, INC.

Geneos Therapeutics

Plymouth Meeting, Pennsylvania, United States

Marilyn Sawyer

DIRECTOR, BRANDING AND CREATIVE, BIOTECHNOLOGY INNOVATION ORGANIZATION

Smaki Test - Edited!

Washington, District of Columbia, United States

Cornelius Schmaltz, MD, MA

HEAD OF UNIT, EUROPEAN INNOVATION COUNCIL (EIC) ACCELERATOR, ENTERPRISE EUROPE NETWORK (EEN)

The big bang in pharma legislation: The European epicenter shaping global healthcare and a competitive industry

Brussels, Belgium

Kim Schmid

EXECUTIVE MANAGING PARTNER, BOWMAN AND BROOKE LLP

Limiting what could be Limitless: Minimizing risk through effective business contingency planning

Minneapolis, Minnesota, United States

Hollie Schmidt, MS

VP SCIENTIFIC OPERATIONS, ACCELERATED CURE PROJECT FOR MULTIPLE SCLEROSIS

Partnering for Progress: Collaborating With Patient Organizations To Advance Therapy Development and Maximize Patient Benefit

Waltham, Massachusetts, United States

Duane Schulthess, MBA

CEO, VITAL TRANSFORMATION

Value of Accelerated Approvals in Context

Washington, District of Columbia, United States

Guy Seabrook, PhD

VP & GLOBAL LEAD, NEUROSCIENCE EXTERNAL INNOVATION, JOHNSON & JOHNSON

Equity by Design: Utility of a Metrics Framework and Metrics To Evaluate Progress on Diversity, Equity, and Inclusion in Clinical Research

South San Francisco, California, United States

Josh Seidenfeld, JD, MBA, BS

PARTNER, COOLEY

Investors' Perspectives - Digital Health Trends and Investment Thesis in 2022 and Beyond

Elisabeth Selph

ASSOCIATE DIRECTOR, CLINICAL PROCUREMENT AND OUTSOURCING, ULTRAGENYX PHARMACEUTICAL

Participant Sensitivity: Amplifying the Voice of the Patient in Clinical Trials

Philadelphia, Pennsylvania, United States

Boitumelo Semete-Makokotlel

CEO, SAHPRA

Building Vaccine Manufacturing Capacity in Africa

RA Session II, MBA

PRESIDENT, FOUNDER AND CEO, TAYSHA GENE THERAPIES

A New Era in Gene Therapy

Dallas, Texas,

Ethan Settembre, PhD

VP, RESEARCH, SEQIRUS

The Future of Flu Protection: Novel Influenza Technologies

Cambridge, Massachusetts, United States

Neha Shah Londoño

DIRECTOR, CLINICAL TRIAL DIVERSITY AND INCLUSION, SEAGEN

Bothell, Washington,

Kunwar Shailubhai

CEO AND CSO, TIZIANA LIFE SCIENCES LTD

Tiziana Life Sciences LTD

New York, New York, United States

Marjan Shamsei, PharmD

VP, HEAD OF COMMERCIAL, ALLOGENE

Out-License, Co-Promote, or Solo-First launch? Insights From an Expert Panel and a Decade of U.S. and EU First-Launch and Partnering Data

South San Francisco, California,

Khushboo Sharma

CHIEF OF STAFF AND SENIOR VICE PRESIDENT, BIO

New Regulatory Policies Creating Opportunities and Considerations for Development Programs

Christi Shaw

CEO, KITE PHARMA, A GILEAD COMPANY

New Regulatory Policies Creating Opportunities and Considerations for Development Programs

Santa Monica, California, United States

Laura Shawver, PhD

CEO, SILVERBACK THERAPEUTICS

How to Survive a Stormy Biotech Season: Thriving in a Challenging Market

Daniel Shelly, PhD

VICE PRESIDENT BUSINESS DEVELOPMENT AND ALLIANCES, PRESCIENT THERAPEUTICS LIMITED

Prescient Therapeutics

Cincinnati, Ohio, United States

Scott Shively

PRESIDENT AND CEO, BEXION PHARMACEUTICALS, INC.

Bexion Pharmaceuticals, Inc

Covington, Kentucky,

John Shoffner

PRIVATE ASTRONAUT-IN-TRAINING

Space & Microgravity as an Innovation Platform for R&D

Tennessee,

Timothy Siegert, PhD

CO-FOUNDER, PRESIDENT & COO, ALLYX THERAPEUTICS

Allyx Therapeutics Inc.

New Haven, Connecticut, United States

Peter Silverstone

CEO & DIRECTOR, ZYLORION HEALTH

Psychedelics: What Will It Take To Get Them to Market?

Calgary, Alberta, Canada

Daniel Simon

SVP BIOPHARMA BUSINESS DEVELOPMENT, GUARDANT HEALTH, INC.

Advancing and Commercializing Longevity Market Innovations — Leveraging Seed Funding, Foundational, and Accelerator Support To Advance Innovations for Older Adults

REDWOOD CITY, California, United States

Dylan Simon

DIRECTORY OF POLICY, EVERYLIFE FOUNDATION FOR RARE DISEASES

Modernizing Newborn Screening: High Patient Impact, Big Challenges

Claire Skentelbery, PhD

DIRECTOR GENERAL, EUROPABIO (THE EUROPEAN ASSOCIATION FOR BIOINDUSTRIES)

The big bang in pharma legislation: The European epicenter shaping global healthcare and a competitive industry

Brussels, Belgium

Henry Skinner

CEO, AMR ACTION FUND

The Silent Pandemic: Tackling Antimicrobial Drug Resistance (AMR)

San Diego, California,

Kevin Skol

SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT, ARCTURUS THERAPEUTICS

Arcturus Therapeutics

San Diego, California, United States

Erika Smith, MBA

CHIEF EXECUTIVE OFFICER, RENETX BIO

Female Founders: Paving the Way for Innovation and Equity

New Haven, Connecticut, United States

Noam Solomon, PhD, BS

CO-FOUNDER AND CEO, IMMUNAI

Artificial Intelligence and Machine Learning: Case Studies in Rare Disease Drug Development

Immunai

New York, New York,

Sasha Spellman, BA

STARTUP COLLABORATION DIRECTOR, AGETECH COLLABORATIVE FROM AARP

Washington,

Chris Springate

CEO, ARC MEDICAL INC.

ARC Medical Inc.

Richmond, British Columbia, Canada

Peter Stein

CDER, FDA

COVID-19 360°: Embedding Global Best Practices in Routine Regulatory Action and Preparing for the Next Pandemic

Julia Strandberg

CHIEF COMMERCIAL OFFICER, PEAR THERAPEUTICS

Understanding the Reimbursement Landscape for Prescription Digital Therapeutics

Boston, Massachusetts,

Jamie Sullivan, MPH

SENIOR DIRECTOR OF POLICY, EVERYLIFE FOUNDATION FOR RARE DISEASES

COVID-19 360°: Embedding Global Best Practices in Routine Regulatory Action and Preparing for the Next Pandemic

Washington, District of Columbia, United States

Shawn Sweeney, PhD

SENIOR DIRECTOR, AACR PROJECT GENIE COORDINATING CENTER, AMERICAN ASSOCIATION FOR CANCER RESEARCH

AACR Project GENIE: Powering Precision Medicine Through an International Consortium and a Pre-Competitive Collaboration With the Biopharmaceutical Industry

Philadelphia, Pennsylvania, United States

Paul Peter Tak

PRESIDENT AND CEO, CANDEL THERAPEUTICS

Candel Therapeutics

Needham, Massachusetts, United States

Ramesh Tharuvai, DrPH

VP, COMMERCIAL MANUFACTURING & SUPPLY CHAIN, NEUROCRINE BIOSCIENCES, INC

Limiting what could be Limitless: Minimizing risk through effective business contingency planning

Pierre Theodore, MD

VP HEALTH EQUITY, J&J

Achieving Global Health Equity with BioPharma and Medtech

San Francisco, California,

Craig Thompson, MBA

CEO, CEREVANCE

CNS Drug Development: Do Biomarkers Hold the Future for Patients?

Andrew Thomson, MA, MSc, PhD

STATISTICIAN, EUROPEAN MEDICINES AGENCY

Complex Innovative Design - What’s in a Name? A Global Perspective on the Changing Design Landscape for Clinical Trials and What That Means for Developers

Is This the End of Global Clinical Trials? What You Need to Know To Navigate the Complex Data Privacy and National Security Restrictions Across International Markets from Europe to China

Amsterdam,

Thomas Tighe, JD

PRESIDENT & CEO, DIRECT RELIEF

Harnessing the Power of Biotechnology on ESG Issues

Santa Barbara, California, United States

Matthew Tremblay, PhD

CHIEF OPERATING OFFICER, THE SCRIPPS RESEARCH INSTITUTE-CALIBR

Feeding the Pipeline

La Jolla, California, United States

Sergi Trilla

CHIEF STRATEGY OFFICER, INTROMMUNE THERAPEUTICS

Intrommune Therapeutics

New York, New York, United States

John Trizzino, BS, MBA

EVP, CHIEF COMMERCIAL OFFICER AND CHIEF BUSINESS OFFICER, NOVAVAX, INC

None of Us are Safe Unless All of Us are Safe: Business Lessons Learned Delivering a Global COVID-19 Vaccine

Gaithersburg, Maryland,

Apostolia Tsimberidou, MD;PhD

PROFESSOR, THE UNIVERSITY OF TEXAS, MD ANDERSON CANCER CENTER

Challenges in Implementing Personalized Medicine in Clinical Practice

Houston, Texas, United States

Malaika Tyson, PhD

SHAREHOLDER, MCANDREWS, HELD & MALLOY

The Roles of AI and Big Data in Precision Healthcare: Perspectives from the Drug Development Pathway and the Patient Journey

chicago, Illinois, United States

Henrietta Ukwu

SENIOR VICE PRESIDENT, CHIEF REGULATORY OFFICER, NOVAVAX

COVID-19 360°: Embedding Global Best Practices in Routine Regulatory Action and Preparing for the Next Pandemic

Washington,

Kwame Ulmer, MBA, BS, MS

ENTREPRENEUR-IN-RESIDENCE, NATIONAL HEART, LUNG AND BLOOD INSTITUTE, NIH

Fostering Diversity and Bio-Equity Through Novel Financing and Training Initiatives in the Aging Innovation Ecosystem

Encino, California, United States

Karolina Valente, PhD

CEO & CSO, VOXCELL BIOINNOVATION

VoxCell BioInnovation

Victoria, British Columbia, Canada

Santosha Vardhana

ATTENDING, MEMORIAL SLOAN KETTERING CANCER CENTER

Defining Correlates of Protection for COVID-19: The Technology is Here, The Time is Now

New York, New York, United States

Dhivya Venkat

CEO, ESYA LABS

CNS Drug Development: Do Biomarkers Hold the Future for Patients?

London, United Kingdom

Maria Vilenchik, PhD

CEO, FELICITEX THERAPEUTICS INC.

Felicitex Therapeutics Inc.

NATICK, Massachusetts, United States

Shafique Virani

CHIEF BUSINESS OFFICER, RECURSION

Maximizing the Potential of Platforms Through Creative and Effective Deal-Making Strategies

Salt Lake City, Utah, United States

Steven Visuri, PhD

CHIEF EXECUTIVE OFFICER, STEM PHARM, INC.

Stem Pharm, Inc

Madison, Wisconsin, United States

Krishnan Viswanadhan, PharmD

PRESIDENT & COO, BE BIOPHARMA

How Do We Make Cell Therapy Sustainable Long Term?

Cambridge, Massachusetts, United States

Vlad Vitoc

FOUNDER & CEO, MAIA BIOTECHNOLOGY, INC.

Maia Biotechnology, Inc.

Chicago, Illinois, United States

Nicole Wagner, PhD

PRESIDENT AND CEO, LAMBDAVISION

Space & Microgravity as an Innovation Platform for R&D

Farmington, Connecticut, United States

D.A. Wallach

MANAGING PARTNER, TIME BIOVENTURES

Complex Innovative Design - What’s in a Name? A Global Perspective on the Changing Design Landscape for Clinical Trials and What That Means for Developers

Los Angeles, California, United States

Eddie Wang Rodriguez

CO-FOUNDER & PARTNER, TEAL VENTURES

Persuasive Pitching – Do You Have the Talent to Engage Investors?

Michael Ward

VICE PRESIDENT OF PUBLIC POLICY AND GOVERNMENT RELATIONS, ALLIANCE FOR AGING RESEARCH

Fireside Chat: The Accelerated Approval Pathway and the Importance to Patients

Washington, District of Columbia, United States

Stan Watowich, PhD

CEO & FOUNDER, RIDGELINE THERAPEUTICS

Ridgeline Therapeutics

Houston, Texas, United States

Neil Weir, PhD

DR, SITRYX THERAPEUTICS LTD

Sitryx Therapeutics

Oxford, United Kingdom

Jim Weissman

FORMER COO & CBO, DICERNA

Maximizing the Potential of Platforms Through Creative and Effective Deal-Making Strategies

Massachusetts,

Frank Wiegand, MD;PhD

CMO, BECKLEY PSYTECH LTD.

Psychedelics: What Will It Take To Get Them to Market?

San Francisco, California, United States

Forrest Williamson

SENIOR ADVISOR, ELI LILLY AND COMPANY

Indianapolis, Indiana, United States

Robert Wills

CHAIRMAN OF THE BOARD, CYMABAY THERAPEUTICS

Cultivating innovation post acquisition: Bayer and Vividion’s arm’s length model

James Wilson, MD, PhD

DIRECTOR, GENE THERAPY PROGRAM, UNIVERSITY OF PENNSYLVANIA, GENE THERAPY PROGRAM AT THE UNIVERSITY OF PENNSYLVANIA

Gene Therapy Pioneers Discuss What's Next for Gene Therapy

Philadelphia, Pennsylvania,

Tom Wilton

CBO, CARISMA THERAPEUTICS

Carisma Therapeutics

Philadelphia, Pennsylvania, United States

Will Wing

DIRECTOR, INNOVATION AND FEASIBILITY, CLINCIERGE

Participant Sensitivity: Amplifying the Voice of the Patient in Clinical Trials

Philadelphia, Pennsylvania, United States

Ashlee Wisdom, MPH

CEO, HEALTH IN HER HUE INC

Solving the Founder/Funder Conundrum to Drive Health Equity and Support Marginalized Communities

Bronx, New York, United States

Blake Wise

CHIEF EXECUTIVE OFFICER, NOVOME BIOTECHNOLOGIES, INC.

Novome Biotechnologies

South San Francisco, California, United States

Nikki Withers

SCIENTIFIC CONTENT WRITER, PERKINELMER

Safety Aspects of AAV- and Lentivirus-based Cell and Gene Therapy

London,

Durhane Wong-Rieger

PRESIDENT & CEO, CANADIAN ORGANIZATION FOR RARE DISORDERS

Global Patient Advocacy – Addressing Health Inequity Across the Globe

Barbara Wood, Esq

EXECUTIVE VICE PRESIDENT, GENERAL COUNSEL & CORPORATE SECRETARY, SELLAS LIFE SCIENCES GROUP, INC.

Utilizing an Existing SPAC To Take Your Private Biotech Company Public

New York, New York, United States

Thomas Wrona

VICE PRESIDENT, INTELLECTUAL PROPERTY , ABSCI CORPORATION

What Happens When Your AI Identifies the Next Big Drug Candidate? Filing for a Patent May Not Be It.

Vancouver, Washington, United States

Roy Wu, MBA

SVP BUSINESS DEVELOPMENT, ATOM BIOSCIENCE

Jiangsu Atom Bioscience & Pharmaceutical Co., Ltd.

San Francisco, California, United States

Aetna Wun Trombley

PRESIDENT AND CEO , LYCIA THERAPEUTICS

From Scientific Breakthrough to Patient Impact: Bringing the Promise of Protein Degrader Therapies to Reality

South San Francisco , California,

Yang Xu

ASSISTANT GENERAL COUNSEL, INTELLECTUAL PROPERTY, BEIGENE USA, INC.

Is This the End of Global Clinical Trials? What You Need to Know To Navigate the Complex Data Privacy and National Security Restrictions Across International Markets from Europe to China

Cambridge, Massachusetts, United States

Wilson Xu, PhD

CHIEF EXECUTIVE OFFICER, BALTO PHARMACEUTICALS, INC.

Balto Pharmaceuticals, Inc.

South Pasadena, California, United States

Rong Yang

CEO, FOSUN PHARMA USA INC.

Fosun Pharmaceuticals

Princeton, New Jersey, United States

Jin San Yoo

CEO AND PRESIDENT, PHARMABCINE, INC.

PharmAbcine Inc.

Daejeon,

Isaac Young, MBA

SENIOR DIRECTOR, GXP PROCUREMENT & SUPPLIER MANAGEMENT, SANGAMO THERAPEUTICS, INC.

Supply chain crisis– forward looking solutions

Richmond, California, United States

Debra Yu, MD, BS

PRESIDENT & CHIEF STRATEGY OFFICER, LIANBIO

Navigating Asia-Pacific Innovation Deal Opportunities

Princeton, New Jersey, United States

Sunita Zalani, PhD

VICE PRESIDENT, ONCOLOGY AND IN-VITRO DIAGNOSTICS, GLOBAL REGULATORY AFFAIRS AND SAFETY, MERCK & CO. INC.

Rahway, New Jersey, United States

Alexandre Zanghellini

CHIEF EXECUTIVE OFFICER, ARZEDA

Arzeda

Seattle, Washington,

Aleksandrs Zavoronkovs

CEO & FOUNDER, INSILICO MEDICINE US, INC.